Showing 1011-1020 of 20877 results for "".
- Sleep Apnea Linked to Higher Incident Glaucoma in Real-World Studyhttps://reachmd.com/news/sleep-apnea-glaucoma-real-world-study/2487817/Key Takeaways Adults evaluated for OSA showed higher later incident glaucoma than sleep-tested controls without OSA. Glaucoma incidence increased stepwise from controls to OSA without a PAP record and was highest in the PAP-record subgroup. Th
- IVUS Guidance In Complex High-Risk PCI Fails To Lower TVFhttps://reachmd.com/news/ivus-guidance-in-complex-high-risk-pci-fails-to-lower-tvf/2487783/Key Takeaways Target-vessel failure occurred more often numerically with IVUS guidance, and a lower primary-endpoint risk was not reported with that strategy. IVUS-guided procedures lasted longer and more often included balloon angioplasty after stent
- Long-Term Air Pollution Exposure Linked to Incident CKDhttps://reachmd.com/news/long-term-air-pollution-exposure-linked-to-incident-ckd/2487775/Key Takeaways Long-term residential exposure to PM2.5, PM10, NO2, and black carbon was associated with modestly higher incident CKD in the main adjusted analysis. The NO2 association was stronger among never-smokers, and NO2 and black carbon remained p
- Intrathecal Morphine Versus Wound Infiltration After Pancreatoduodenectomyhttps://reachmd.com/news/intrathecal-morphine-versus-wound-infiltration-after-pancreatoduodenectomy/2487776/Key Takeaways Single-shot intrathecal morphine was noninferior to continuous wound infiltration for the primary mean pain score outcome after open pancreatoduodenectomy. Intrathecal morphine was also noninferior for mean resting pain, with lower early
- Ramucirumab Plus Docetaxel Shows Phase II Activity in Gastric Cancerhttps://reachmd.com/news/ramucirumab-plus-docetaxel-shows-phase-ii-activity-in-gastric-cancer/2487782/Key Takeaways The combination was associated with measurable activity, with disease control reported in nearly three quarters of patients. The findings came from a multicenter, single-arm phase II trial of 35 patients who were refractory or intolerant
- Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edemahttps://reachmd.com/news/interleukin-6-inhibition-with-vamikibart-for-uveitic-macular-edema/2487788/Key Takeaways Intravitreal vamikibart was associated with week 12 improvement in visual acuity and retinal thickness across all three dose groups. Ocular adverse events were reported in 19 of 37 participants, with one unrelated serious event, one treat
- Report: Dermatology M&A Momentum Sets Sights on Independent Practiceshttps://reachmd.com/news/dermatology-ma-momentum-continues-as-buyers-chase-independent-practices/2487714/Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners.
- Parent Mental Health Interventions in the NICUhttps://reachmd.com/news/parent-mental-health-interventions-in-the-nicu/2487729/Key Takeaways The review included 160 studies, 16,639 parents, and 85 meta-analysis estimates assessing anxiety, depression, stress, and trauma symptoms with validated self-report questionnaires. Anxiety improved with bonding interventions, family-centered c
- Consensus Panel Offers First Standardized Imaging Framework for High-Risk CSCChttps://reachmd.com/news/consensus-panel-offers-first-standardized-imaging-framework-for-high-risk-cscc/2487708/A multidisciplinary panel of experts has developed consensus recommendations to help standardize staging and surveillance imaging for patients with localized cutaneous squamous cell carcinoma (cSCC), publishing the recommendations online in
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://reachmd.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode